Access
To read this story in full you will need to login or make a payment (see right).
Opinion
Nature 416, 109 (14 March 2002) | doi:10.1038/416109a
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Manager Scientific Writing
- Indegene Lifesystems Pvt. Ltd
- Bengaluru 560 071 India
Full-Professor of Heart and Thoracic Surgery (W3) (f / m)
- Friedrich-Schiller-University Jena
- Jena Germany
Beyond the cloning debate
Top of page
Abstract
Arguments over human embryonic stem cells and cloning have loomed large over the choice of a new director of the National Institutes of Health. But the expected nominee for the position will need to prove himself on other fronts.
Within the next month or two, the US Senate will vote on a bill that would ban research into therapeutic cloning — the creation of cloned human embryos to extract embryonic stem (ES) cells matched to individual patients. The result is too close to call, and lobbying for and against has reached fever pitch.
To read this story in full you will need to login or make a payment (see right).
